Osilodrostat
Lua error in Module:Infobox at line 166: malformed pattern (missing ']').
Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome).[1][2] It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1).[2] The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications.[1] As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.[1]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
- Pages with reference errors
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antiglucocorticoids
- Imidazoles
- Nitriles
- Organofluorides
- Pyrroles
- Steroid 11β-hydroxylase inhibitors
- Systemic hormonal preparation stubs